23 Feb Startup Gregor Diagnostics advances novel diagnostic technology
Tobias Zutz found himself seeking a new challenge in 2015.
With a R&D experience in assay development and molecular diagnostics, he had been a member of the R&D team at Exact Sciences that developed Cologuard, a non-invasive screening test for colorectal cancer.
So Zutz met with Wisconsin Alumni Research Foundation Director of Licensing Jennifer Gottwald, whom he knew from their Master’s in Biotechnology program at UW–Madison, to look at WARF’s patent portfolio and discuss diagnostic technologies that could be licensed and potentially commercialized.
“One that wasn’t on my list was these methylated DNA biomarkers for prostate cancer, and she put me in touch with David Jarrard, the associate director of translational research at the Carbone Cancer Center, who had discovered those biomarkers,” says Zutz.
Zutz licensed the technology from WARF and founded Gregor Diagnostics.